What’s Propelling Aptevo Therapeutics Inc. (APVO) to Reach 52-Week High?

May 18, 2018 - By Rodney Autry

The stock of Aptevo Therapeutics Inc. (NASDAQ:APVO) hit a new 52-week high and has $6.44 target or 8.00 % above today’s $5.96 share price. The 7 months bullish chart indicates low risk for the $133.75 million company. The 1-year high was reported on May, 18 by Barchart.com. If the $6.44 price target is reached, the company will be worth $10.70M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.34% or $0.02 during the last trading session, reaching $5.96. About 18,584 shares traded. Aptevo Therapeutics Inc. (NASDAQ:APVO) has risen 72.19% since May 18, 2017 and is uptrending. It has outperformed by 60.64% the S&P500.

Analysts await Aptevo Therapeutics Inc. (NASDAQ:APVO) to report earnings on August, 9. They expect $-0.52 EPS, up 1.89 % or $0.01 from last year’s $-0.53 per share. After $-0.63 actual EPS reported by Aptevo Therapeutics Inc. for the previous quarter, Wall Street now forecasts -17.46 % EPS growth.

More notable recent Aptevo Therapeutics Inc. (NASDAQ:APVO) news were published by: Globenewswire.com which released: “Aptevo Therapeutics Announces IND Submission for APVO436” on May 01, 2018, also Globenewswire.com with their article: “Aptevo Therapeutics Reports First Quarter 2018 Financial Results” published on May 10, 2018, Benzinga.com published: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” on May 16, 2018. More interesting news about Aptevo Therapeutics Inc. (NASDAQ:APVO) were released by: Benzinga.com and their article: “45 Biggest Movers From Yesterday” published on May 16, 2018 as well as Nasdaq.com‘s news article titled: “Report: Developing Opportunities within Natus Medical, Aptevo Therapeutics, Revlon, Silgan, Resources Connection …” with publication date: April 30, 2018.

Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. The company has market cap of $133.75 million. The Company’s marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. It has a 41.97 P/E ratio. The companyÂ’s marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.